Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
Submitted by
admin
on October 8, 2021 - 10:58am
Source:
Motley Fool
News Tags:
COVID-19
Merck
Ridgeback Therapeutics
Roche
Atea Pharmaceuticals
AT-527
antivirals
Headline:
Can This Duo Outperform Merck and Ridgeback Biotherapeutics' COVID Treatment?
snippet:
Merck has good data, but Atea has more growth potential.
Backing from Roche should ease concerns about the pharma's small size.
Do Not Allow Advertisers to Use My Personal information
